Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers
Triple-negative breast cancer (TNBC) represents a challenge clinically due to a lack of response to hormonal and HER2-targeted agents coupled with an aggressive disease course. As the biology of this breast cancer subtype is better understood, it is clear that TNBC is a heterogeneous disease and one...
Main Authors: | S. Lindsey Davis, S. Gail Eckhardt, John J. Tentler, Jennifer R. Diamond |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2014-05-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834013519843 |
Similar Items
-
Can MRI Biomarkers Predict Triple-Negative Breast Cancer?
by: Giuliana Moffa, et al.
Published: (2020-12-01) -
Genome Instability-Derived Genes Are Novel Prognostic Biomarkers for Triple-Negative Breast Cancer
by: Maoni Guo, et al.
Published: (2021-07-01) -
Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer
by: Todd M. Pitts, et al.
Published: (2020-03-01) -
Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer
by: Jiande Wu, et al.
Published: (2020-06-01) -
Triple-Negative Breast Cancer
by: Quyen D. Chu, et al.
Published: (2012-01-01)